Approximately 60% of NSCLC patients with adenocarcinoma harbor oncogenic driver mutations, with the epidermal growth factor receptor (EGFR) mutation being the most commonly found and targetable driver mutation in NSCLC (3). Here, EGFR is linked to adenocarcinoma.